首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症

市場調查報告書

商品編碼

1654677

全球乳癌篩檢與診斷技術市場 - 2025 至 2033 年

Global Breast Cancer Screening and Diagnostic Techniques Market - 2025-2033

出版日期: 2025年02月13日 | 出版商:

DataM Intelligence | 英文 168 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球乳癌篩檢和診斷技術市場規模達到 68 億美元，預計到 2033 年將達到 117 億美元，2025-2033 年預測期內的複合年成長率為 6.3%。

乳癌篩檢和診斷技術是指在症狀出現之前或在出現症狀的個體中用於檢測、診斷和評估乳癌的一系列醫療程序、測試和技術。這些方法旨在儘早發現乳癌，並提高成功治療和存活的機會。

篩檢包括檢查沒有任何明顯症狀的人是否有乳癌跡象，目的是在治療最有效時儘早發現癌症。一旦透過篩檢發現潛在異常，就會使用診斷技術來確認是否是癌症並評估其類型和程度。

受乳癌發病率上升、技術進步以及對早期檢測重要性的認知不斷提高等因素推動，乳癌篩檢和診斷技術市場的需求正在不斷成長。例如，粉紅絲帶運動和乳癌宣傳月（十月）等計劃大大提高了全球意識，鼓勵女性定期接受檢查。

市場動態：

促進因素與約束因素

乳癌發生率上升

乳癌盛行率的上升極大地推動了乳癌篩檢和診斷技術市場的成長，並預計將在預測期內推動市場的發展。乳癌是目前全球最常見的癌症，由於人口老化、生活方式改變和診斷能力提高等因素，其盛行率持續增加。這直接影響對早期檢測和診斷技術的需求。

例如，根據世界衛生組織 (WHO) 的數據，2022 年有 230 萬名女性被診斷出罹患乳癌。乳癌影響青春期後各年齡層的女性，但其發生率在後期有所上升。此外，根據乳癌組織的數據，到 2024 年，美國約有 310,720 名女性被診斷出患有侵襲性乳癌，其中 16% 是年齡在 50 歲以下的女性。病例數量的不斷成長推動了對全面篩檢和診斷工具的需求，以便儘早發現和治療。

由於生活方式的改變和遺傳傾向導致乳癌發生率上升，對預防篩檢和診斷技術的需求也日益成長。有乳癌家族史或基因突變（如 BRCA1/2）的女性罹患乳癌的風險更高。基因檢測正變得越來越普及，高風險女性對此的需求也越來越大。

人工智慧診斷的準確性和標準化有限

人工智慧（AI）融入乳癌篩檢和診斷具有重大的前景。然而，準確性有限和缺乏標準化等挑戰阻礙了其廣泛應用。在非多樣化資料集上訓練的人工智慧模型可能無法很好地推廣到不同人群。例如，使用某一人口統計資料開發的人工智慧系統在應用於另一個人口統計資料時可能會表現不佳，導致診斷結果不一致。這種多變性可能導致假陽性和假陰性，從而破壞對人工智慧診斷的信任。

人工智慧演算法可能難以識別特定形式的乳癌，例如間隔癌（IC），這種癌症具有侵襲性並且通常無法透過標準篩檢方法發現。儘管人們努力提高檢測能力，但 IC 仍佔已檢測到的乳癌的約 30%，而 AI 在提高其檢測能力方面的成功率有限。

市場領導者和先驅者
- 新興先鋒和傑出參與者
- 擁有最大銷售品牌的成熟領導者
- 擁有成熟產品的市場領導者
新興創業公司和關鍵創新者
CXO 觀點
最新進展與突破
案例研究/正在進行的研究
監管和報銷情況
- 北美洲
- 歐洲
- 亞太地區
- 拉丁美洲
- 中東和非洲
波特五力分析
供應鏈分析
專利分析
SWOT 分析
未滿足的需求和差距
市場進入和擴張的推薦策略
情境分析：最佳情況、基本情況和最壞情況預測
定價分析和價格動態

第 5 章：乳癌篩檢和診斷技術市場（按產品類型）

篩檢設備
診斷試劑盒和檢測試劑
切片設備
軟體和基於人工智慧的檢測工具

第 6 章：乳癌篩檢與診斷技術市場（按技術）

影像技術
- 乳房X光檢查
- 超音波
- 電腦斷層掃描
- 磁振造影
- 其他
切片技術
基因和生物標記檢測

第 7 章：乳癌篩檢和診斷技術市場（按最終用戶分類）

醫院
專科診所
診斷影像中心
研究實驗室
其他

第 8 章：乳癌篩檢和診斷技術市場，按區域市場分析和成長機會

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
南美洲
- 巴西
- 阿根廷
- 南美洲其他地區
亞太
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲

第9章：競爭格局與市場定位

競爭概況和主要市場參與者
市佔率分析與定位矩陣
策略夥伴關係、併購
產品組合和創新的關鍵發展
公司基準化分析

第10章：公司簡介

GE HealthCare

公司概況
產品組合和描述
財務概覽
關鍵進展
SWOT 分析

Hologic, Inc.
Koninklijke Philips NV
Siemens Healthineers AG
FUJIFILM Holdings Corporation
Myriad Genetics, Inc.
F. Hoffmann-La Roche Ltd
Danaher Corporation
QIAGEN NV
Bio-Rad Laboratories, Inc.

第 11 章：假設與研究方法

資料收集方法
數據三角測量
預測技術
數據驗證和確認

第 12 章：附錄

簡介目錄

Product Code: MI4115

The global breast cancer screening and diagnostic techniques market reached US$ 6.8 billion in 2024 and is expected to reach US$ 11.7 billion by 2033, growing at a CAGR of 6.3% during the forecast period 2025-2033.

Breast cancer screening and diagnostic techniques refer to a range of medical procedures, tests, and technologies used to detect, diagnose, and evaluate breast cancer, either before symptoms appear or in individuals presenting with symptoms. These methods aim to identify breast cancer in its earliest stages, improving the chances of successful treatment and survival.

Screening involves checking for signs of breast cancer in people who do not have any noticeable symptoms, with the goal of detecting cancers early when treatment is most effective. Once a potential abnormality is identified through screening, diagnostic techniques are used to confirm whether it is cancer and to assess its type and extent.

The breast cancer screening and diagnostic techniques market is experiencing increasing demand, driven by factors such as a rising incidence of breast cancer, advances in technology, and growing awareness of the importance of early detection. For instance, initiatives such as the Pink Ribbon Campaign and Breast Cancer Awareness Month (October) have significantly increased global awareness, encouraging women to undergo regular screening.

Market Dynamics: Drivers & Restraints

Rising prevalence of breast cancer

The rising prevalence of breast cancer is significantly driving the growth of the breast cancer screening and diagnostic techniques market and is expected to drive the market over the forecast period. Breast cancer is now the most commonly diagnosed cancer worldwide, with its prevalence continuously increasing due to factors like population aging, lifestyle changes, and improved diagnostic capabilities. This directly impacts the demand for early detection and diagnostic technologies.

For instance, according to the World Health Organization (WHO), in 2022, 2.3 million women were diagnosed with breast cancer. Breast cancer affects women of all ages after puberty, although the incidence rises later in life. Additionally, according to the Breast Cancer Organization, in 2024, approximately 310,720 women diagnosed with invasive breast cancer, 16% of which will be in women younger than 50 years of age in the United States. The growing number of cases drives the need for comprehensive screening and diagnostic tools for early detection and treatment.

As lifestyle changes and genetic predispositions contribute to the rising incidence of breast cancer, the need for preventive screening and diagnostic techniques grows. Women with a family history of breast cancer or genetic mutations (like BRCA1/2) are at a much higher risk. Genetic testing, which is becoming more widely available, is in high demand for women at elevated risk.

Limited accuracy & standardization in AI-driven diagnostics

The integration of Artificial Intelligence (AI) into breast cancer screening and diagnostics holds significant promise. However, challenges related to limited accuracy and lack of standardization are impeding its widespread adoption. AI models trained on non-diverse datasets may not generalize well across varied populations. For instance, an AI system developed using data from one demographic may underperform when applied to another, leading to inconsistent diagnostic outcomes. This variability can result in both false positives and false negatives, undermining trust in AI-driven diagnostics.

AI algorithms may struggle to identify specific forms of breast cancer, such as interval cancers (ICs), which are aggressive and often elude standard screening methods. Despite efforts to enhance detection, ICs account for approximately 30% of detected breast cancers, and AI's success in improving their detection has been limited.

Segment Analysis

The global breast cancer screening and diagnostic techniques market is segmented based on product type, technology, end-user and region.

Product Type:

The imaging techniques segment is expected to dominate the breast cancer screening and diagnostic techniques market share

Mammography remains the gold standard in breast cancer screening, which significantly drives the demand for imaging technologies in this market. Mammography is highly effective in detecting early-stage breast cancer, particularly in women over 40. The technique allows radiologists to identify suspicious lumps, microcalcifications, or other abnormalities that could indicate cancer.

For instance, in November 2024, GE HealthCare launched its new Pristina Via mammography system which is designed to enhance the breast screening experience for both technologists and patients. Pristina enhancements will help decrease repetitive tasks and improve processes, allowing mammography techs to concentrate on delivering quality and personalized care.

Ultrasound is frequently used as a supplementary imaging technique alongside mammography to further assess abnormalities or to guide biopsies. Ultrasound is particularly beneficial for women with dense breast tissue, where mammograms might miss certain cancers. It is also effective in distinguishing between solid tumors and benign cysts, reducing unnecessary biopsies.

For instance, in December 2024, the novel ultrasound measurement and monitoring technology launched for early breast cancer detection. This Sona's technology enables women to proactively monitor their breast health before they are old enough to access a mammogram. It enables healthcare providers to provide timely personalised screening through simple, safe and low-cost access to breast density information, which is currently limited by a woman's age and use of traditional mammograms.

Geographical Analysis

North America is expected to hold a significant position in the breast cancer screening and diagnostic techniques market share

The rising number of breast cancer cases in North America especially in the United States and Canada is a significant driver for the increased demand for screening and diagnostic techniques in the region. According to the Breast Cancer Organization, 310,720 women diagnosed with invasive breast cancer. This high incidence directly translates to a growing need for screening and diagnostic technologies.

Additionally, according to the Canadian Cancer Society, in 2022, an estimated 28,600 Canadian women diagnosed with breast cancer. Breast cancer is responsible for around 25% of new cancer diagnoses and among Canadian women. One in every eight women is anticipated to acquire breast cancer over her lifetime. This contributes to the high demand for early detection technologies.

Awareness campaigns and high public knowledge about the importance of early breast cancer detection have significantly increased demand for screening and diagnostic tests in North America. For instance, October is recognized as Breast Cancer Awareness Month in North America, during which public campaigns increase awareness about the importance of routine screening and early detection, driving higher participation in screening programs.

Asia-Pacific is growing at the fastest pace in the breast cancer screening and diagnostic techniques market

Many Asia-Pacific countries are investing significantly in improving healthcare infrastructure, which is directly impacting the adoption of advanced breast cancer screening and diagnostic techniques. Countries like China, India, Japan, and South Korea are making substantial investments in healthcare infrastructure. For instance, China and India has implemented national cancer screening programs that increase access to mammography and ultrasound technologies in rural areas.

The rise of private hospitals and healthcare facilities in countries like India and Southeast Asia has significantly increased access to advanced breast cancer diagnostic tools. Major private hospitals in cities like Mumbai and Singapore now offer state-of-the-art diagnostic services, including 3D mammography, MRI, and AI-powered diagnostics. For instance, in December 2024, Deepak Phenolics Limited unveiled a transformative initiative with the launch of a Mobile Mammography Van (MMV) designed to detect breast cancer at its early stages.

The rising awareness about breast cancer and increasing governmental support in the APAC region especially in India and China are pivotal to the growth of the screening and diagnostic market. For instance, in January 2025, Fujifilm India launched brand film Maa's fight through my eyes under the series Stories of More Smiles, highlighting breast cancer awareness initiative

Competitive Landscape

The major global players in the breast cancer screening and diagnostic techniques market include GE HealthCare, Hologic, Inc., Koninklijke Philips N.V., Siemens Healthineers AG, FUJIFILM Holdings Corporation, Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd, Danaher Corporation, QIAGEN N.V., Bio-Rad Laboratories, Inc. and among others.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Breast Cancer Screening and Diagnostic Techniques market report delivers a detailed analysis with 62 key tables, more than 55 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Market Introduction and Scope

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. Executive Insights and Key Takeaways

2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Technology
2.5. Snippet by End-User
2.6. Snippet by Region

3. Dynamics

3.1. Impacting Factors
- 3.1.1. Drivers
  - 3.1.1.1. Rising Prevalence of Breast Cancer
- 3.1.2. Restraints
  - 3.1.2.1. Limited Accuracy & Standardization in AI-Driven Diagnostics
- 3.1.3. Opportunity
- 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

4.1. Market Leaders and Pioneers
- 4.1.1. Emerging Pioneers and Prominent Players
- 4.1.2. Established leaders with largest selling Brand
- 4.1.3. Market leaders with established Product
4.2. Emerging Startups and Key Innovators
4.3. CXO Perspectives
4.4. Latest Developments and Breakthroughs
4.5. Case Studies/Ongoing Research
4.6. Regulatory and Reimbursement Landscape
- 4.6.1. North America
- 4.6.2. Europe
- 4.6.3. Asia Pacific
- 4.6.4. Latin America
- 4.6.5. Middle East & Africa
4.7. Porter's Five Force Analysis
4.8. Supply Chain Analysis
4.9. Patent Analysis
4.10. SWOT Analysis
4.11. Unmet Needs and Gaps
4.12. Recommended Strategies for Market Entry and Expansion
4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.14. Pricing Analysis and Price Dynamics

5. Breast Cancer Screening and Diagnostic Techniques Market, By Product Type

5.1. Introduction
- 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 5.1.2. Market Attractiveness Index, By Product Type
5.2. Screening Devices*
- 5.2.1. Introduction
- 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Diagnostic Kits & Assays
5.4. Biopsy Devices
5.5. Software & AI-based Detection Tools

6. Breast Cancer Screening and Diagnostic Techniques Market, By Technology

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 6.1.2. Market Attractiveness Index, By Technology
6.2. Imaging Techniques*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.2.3. Mammography
- 6.2.4. Ultrasound
- 6.2.5. Computed Tomography
- 6.2.6. Magnetic Resonance Imaging
- 6.2.7. Others
6.3. Biopsy Techniques
6.4. Genetic and Biomarker Testing

7. Breast Cancer Screening and Diagnostic Techniques Market, By End-User

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Diagnostic Imaging Centers
7.5. Research Laboratories
7.6. Others

8. Breast Cancer Screening and Diagnostic Techniques Market, By Regional Market Analysis and Growth Opportunities

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 8.1.2. Market Attractiveness Index, By Region
8.2. North America
- 8.2.1. Introduction
- 8.2.2. Key Region-Specific Dynamics
- 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.2.6.1. U.S.
  - 8.2.6.2. Canada
  - 8.2.6.3. Mexico
8.3. Europe
- 8.3.1. Introduction
- 8.3.2. Key Region-Specific Dynamics
- 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.3.6.1. Germany
  - 8.3.6.2. U.K.
  - 8.3.6.3. France
  - 8.3.6.4. Spain
  - 8.3.6.5. Italy
  - 8.3.6.6. Rest of Europe
8.4. South America
- 8.4.1. Introduction
- 8.4.2. Key Region-Specific Dynamics
- 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.4.6.1. Brazil
  - 8.4.6.2. Argentina
  - 8.4.6.3. Rest of South America
8.5. Asia-Pacific
- 8.5.1. Introduction
- 8.5.2. Key Region-Specific Dynamics
- 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.5.6.1. China
  - 8.5.6.2. India
  - 8.5.6.3. Japan
  - 8.5.6.4. South Korea
  - 8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
- 8.6.1. Introduction
- 8.6.2. Key Region-Specific Dynamics
- 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking

10. Company Profiles

10.1. GE HealthCare*
- 10.1.1. Company Overview
- 10.1.2. Product Portfolio and Description
- 10.1.3. Financial Overview
- 10.1.4. Key Developments
- 10.1.5. SWOT Analysis
10.2. Hologic, Inc.
10.3. Koninklijke Philips N.V.
10.4. Siemens Healthineers AG
10.5. FUJIFILM Holdings Corporation
10.6. Myriad Genetics, Inc.
10.7. F. Hoffmann-La Roche Ltd
10.8. Danaher Corporation
10.9. QIAGEN N.V.
10.10. Bio-Rad Laboratories, Inc.